SCHEMBL4530715

SCHEMBL4530715

CCOc1cc(OC)cc(F)c1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.42
CALM1 P0DP23 2/20 0.41
ABL1 P00519 1/20 0.38
ABCB1 P08183 1/20 0.38
BCR P11274 1/20 0.38
TUBB1 Q9H4B7 1/20 0.37
ESR1 P03372 2/20 0.37
AHR P35869 1/20 0.37
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 3/20 0.36
NCOA1 Q15788 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
GAA P10253 1/20 0.35
HSD17B10 Q99714 3/20 0.35
MAPK1 P28482 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4523979 0.83 TAAR1 (0.40) TAAR1HPGDSMN1; SMN2KDM4EMAPT
SCHEMBL30083748 0.83 TAAR1 (0.44) TAAR1SMN1; SMN2MAPTL3MBTL1GAA
SCHEMBL1042615 0.83 TAAR1 (0.44) TAAR1SMN1; SMN2MAPTL3MBTL1GAA
SCHEMBL1552502 0.78 ALDH1A1 (0.50) TAAR1ALDH1A1CYP1A2
SCHEMBL17543789 0.77 NQO1 (0.44) HPGDSMN1; SMN2KDM4ELMNAL3MBTL1
SCHEMBL15295356 0.75 TAAR1 (0.48) TAAR1CALM1ABL1ABCB1BCR
SCHEMBL12093386 0.74 HTT (0.47) CALM1TUBB1ESR1AHRKDM4E
SCHEMBL17357094 0.74 TUBB1 (0.49) TAAR1CALM1TUBB1HPGDSMN1; SMN2
SCHEMBL28753938 0.74 RAB9A (0.35) HPGDSMN1; SMN2KDM4ELMNAMAPT
SCHEMBL25085876 0.73 HTR1A (0.43) SMN1; SMN2KDM4ELMNAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors BERTHEL STEVEN JOSEPH 2009-04-23 US disclosed
EP-1812409-A1 AMINOQUINAZOLINES COMPOUNDS F. Hoffmann-Roche AG (CH) 2007-08-01 EP disclosed
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2006-09-21 US disclosed
WO-2006050843-A1 AMINOQUINAZOLINES COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105477-A1 Quinazoline Protein Tyrosine Phosphatase Inhibitors PTPN5, PTPN1, PTPN7 TAAR1 1668/4885CALM1 1973/4885ABL1 42/4885
US-20060211715-A1 Quinazoline protein tyrosine phosphatase inhibitors PTPN5, PTPN1, PTPN7 TAAR1 1668/4885CALM1 1973/4885ABL1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.